Professor Bruce Freeman: Keynote Speaker of the 26th International Conference of the Redox Medicine Society
SCIENMAG: Medicine & Health
MARCH 26, 2024
Credit: Redox Medicine […]
Drug Development International Small Molecule 
Unlocking Undruggable Targets: Shifting Paradigms in Modern Drug Discovery
DrugBank
MAY 15, 2024
Its structure makes it incredibly difficult for drugs to bind effectively, which has stymied drug development for decades. The binding pockets on KRAS are shallow and polar , not ideal for the kinds of interactions needed for strong, effective drug binding. One approach is to look beyond the traditional drug molecule.
Join 15,000+
Insiders
Sign Up for our Newsletter
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Trending Sources
Future trends: biopharma to outpace small molecule drug development
Drug Discovery World
FEBRUARY 22, 2023
More than 20% of new drugs are now coming from small innovative organisations and this percentage is increasing exponentially as these small organisations adopt this new technology. The supply chain design needs to be reviewed and difficult decisions about downsizing the internal supply footprint need to be made.
Small Molecule 
130
130 
This week in drug discovery (17-21 October)
Drug Discovery World
OCTOBER 21, 2022
Enanta Pharmaceuticals, a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, has dosed the first subject in its Phase I clinical trial of EDP-323, a novel, oral L-protein inhibitor in development for the treatment of respiratory syncytial virus (RSV). .
Small Molecule 130
130 
Key industry partnerships advancing drug discovery
Drug Discovery World
DECEMBER 26, 2023
Anagenex and Nimbus Therapeutics Anagenex and Nimbus Therapeutics have initiated a research collaboration to discover small molecule drugs for multiple challenging targets. Peter Tummino, Nimbus’ Chief Scientific Officer, said: “At Nimbus, we have prioritised important but difficult-to-drug targets across multiple therapy areas.
Small Molecule 130
130 
Looking ahead to AACR
Drug Discovery World
APRIL 6, 2023
These topics will be represented across a range of session types, including methods workshops, minisymposia, poster and plenary sessions, as well as keynotes, awards and lectures.
Small Molecule 130
130 
Turning science into business: Merging AI and RNA
Drug Discovery World
FEBRUARY 27, 2023
For founders planning to launch their start-ups, specifically drug developers, there needs to be sound, foundational science with promising data that will enable you to push further down the drug discovery pipeline. Do you have any therapeutic targets in mind for your first small molecule drug candidate?
RNA 130
130 
Condensate biology: advancing drug discovery for complex diseases
Drug Target Review
JULY 13, 2023
By capitalising on condensate biology, Dewpoint seeks to tackle diseases and targets that have previously lacked sufficient understanding for effective drug discovery. Dewpoint addresses diseases that lacked comprehensive biological understanding, allowing for more meaningful and logical drug discovery efforts.
Disease 98
98 
Sentiment & Themes Emerging From JPM 2024
LifeSciVC
JANUARY 16, 2024
The expectation that Pharma will continue buy-ups here is helping to fuel conviction for another strong year ahead for M&A, especially for those acquirers who will rely on inorganic acquisition to build in areas under-represented by internal R&D (e.g., Small molecule GLP1s?
Small Molecule 139
139 
The power of combinations in blood cancers
Drug Target Review
NOVEMBER 6, 2023
To bring us closer to curing cancer, a combination of effective drugs with non-overlapping mechanisms of action is required. 6 In all these examples, an effective backbone drug was first developed, before adding one or more drugs to establish the new regimens. References Blood Cancer UK. link] Accessed October 2023.
Small Molecule 111
111 
Where is the drug discovery expertise happening in the UK?
Drug Discovery World
OCTOBER 16, 2023
A company within this ecosystem is STORM Therapeutics, a clinical stage biotechnology company creating novel small molecule therapies that inhibit RNA modifying enzymes (RME) for use in oncology and other diseases. The UK is additionally able to serve the US market with excellent international cultural and linguistic links.
Drugs 189
189 
AI Tool CHIEF Paints a Landscape of a Cancer, Refining Diagnosis, Treatment, and Prognosis
PLOS: DNA Science
SEPTEMBER 5, 2024
The most groundbreaking cancer drug approval was for Gleevec , with a mere 3-month trajectory at FDA before its approval in 2001. Gleevec is a small molecule that interferes with entry of an enzyme – a tyrosine kinase – that enables growth signals to enter specific cells and trigger division.
Treatment 52
52 
Unlocking AI’s potential in drug discovery: A roadmap to scalable solutions
Drug Discovery World
SEPTEMBER 9, 2024
This capability allows AI to identify potential treatment strategies that consider multiple factors simultaneously, leading to the discovery of drug candidates that might not have been previously considered. By providing researchers with valuable insights, AI can help develop drugs targeting complex and hard-to-treat diseases.
Drugs 162
162 
Global start-ups: where is the innovation?
Drug Discovery World
APRIL 25, 2023
Dawn Bio which is a drug discovery platform based on human embryo models for drug development for women’s reproductive health. In total, BII’s start-ups have raised over €333 million in external funding from both local and international investors.
Science 130
130 
Evaluating Impurities in New Drugs to Prevent Delays in Development
The Premier Consulting Blog
JULY 9, 2023
During the development of new small molecule drug products, developers must conduct impurity and degradant evaluation at several points in the program and to varying degrees. Global regulatory agencies, including the U.S. Global regulatory agencies, including the U.S.
Why project management holds the key to efficient drug development
Drug Discovery World
AUGUST 5, 2022
Ian Hollingsworth, Associate Director of product development at Boyds, the global drug development consultancy, explains the benefits to the drug development lifecycle of building strong partnerships with external consultants, and when and how to get the best from them. Why sponsors use external consultants.
Drug Development 130
130 
Claims that AI will “revolutionise pharma R&D” are (almost entirely) hype
DrugBaron
JANUARY 31, 2024
A simple example is called projection, where simple linear combinations of the data are used to extract the internal patterns within very large datasets – tools that were rightly called pattern recognition methods. And pattern recognition is not intelligence.
Pharma R&D 165
165 
Inflection Biosciences Announces Appointment of Gregory I. Berk, MD, to its Board of Directors
The Pharma Data
OCTOBER 18, 2020
DUBLIN–( BUSINESS WIRE )– Inflection Biosciences Ltd , a company developing innovative therapeutics for the treatment of cancer, today announced the appointment of industry veteran Gregory I. Greg possesses a wealth of experience in developing new cancer therapeutics across multiple U.S. Berk, MD, to its Board of Directors.
Combining autotaxin and TGF-? inhibitors in cancer
Drug Target Review
NOVEMBER 22, 2023
Whilst TGF-β is an attractive target for cancer therapy because of its critical role in promoting tumor aggressiveness, immune escape and resistance to therapy, activation of alternative resistance pathways has hindered drug development attempts in the past.
Licensing 52
52 
Mission Therapeutics Appoints Dr Suhail Nurbhai as Chief Medical Officer
The Pharma Data
NOVEMBER 1, 2020
Mission Therapeutics is an early-stage drug development company targeting the ubiquitin pathway for the treatment of kidney disease, neurodegenerative disease, rare mitochondrial diseases and fibrosis. The Company is managed by a team with broad international, commercial and clinical-science experience.
Top 10 Drug Discovery Trends at the Top 20 Pharma
PerkinElmer
FEBRUARY 18, 2021
Which high throughput screening (HTS) approach is the most productive in finding hits for drug development: target-based or phenotypic? Small molecules are making a comeback. Outsourcing is filling internal gaps when it comes to screening. It is an ongoing debate.
Polymorph profiling with X-ray powder diffraction protects patents and patients
Drug Discovery World
DECEMBER 7, 2022
Small molecules can face big challenges . Despite the emergence of, and excitement around, advanced therapeutic modalities, traditional small molecule pharmaceuticals still occupy a significant and steadily growing share of the market. By Dr Natalia Dadivanyan , Segment Marketing Manager, Malvern Panalytical .
Small Molecule 130
130 
Global advances in synthetic biology
Drug Discovery World
NOVEMBER 17, 2022
However, the development of drugs takes decades which is too long for most biotech start- ups looking for fast-track drug development programs. Antibiotic drug discovery once largely consisted of scientists growing streptomyces or bacillus in the lab and bottling their secrets to treat human disease. .
Engineering 130
130 
Navigating the Challenges in Clinical Research for Hepatitis C Therapies
Vial
DECEMBER 11, 2023
Hepatitis C Virus (HCV) Drug Development There is an urgent need to develop novel, efficient, reliable, and cost-effective diagnostic technologies and therapeutic and immune prophylactic interventions to manage HCV. The Food and Drug Administration (FDA) approved and recommended dozens of small-molecule drugs.
The Achilles’ heel of cancer
Drug Discovery World
AUGUST 2, 2023
For instance, protein palmitoylation involves the covalent attachment of fatty acyl chains, typically a palmitate to internal cysteine residues of a protein via labile thioester linkages. Ezurpimtrostat (GNS561) was identified from a large library of small molecules as a lead compound for drug development.
Small Molecule 130
130 
Analysis Life Sciences Thank You Meet C3TI, FDA’s new clinical trial innovation hub
Agency IQ
APRIL 19, 2024
As the FDA’s Center for Drug Evaluation and Research (CDER) characterized it in a 2023 call for comments : “Evolving understanding of disease biology and molecular pharmacology, advancements in drug discovery, and growth in novel therapeutic platforms (i.e., In particular, regulations in both the U.S.
Enlisting Monoclonal Antibodies in the Fight Against COVID-19
NIH Director's Blog: Drug Development
MAY 21, 2020
One advantage of this class of therapeutics is that the timelines for their development, testing, and approval are typically shorter than those for drugs made of chemical compounds, called small molecules.
Virus 52
52 
Novel inhibitors could become new anticancer therapeutics
Drug Discovery World
OCTOBER 4, 2023
University of Queensland (UQ) researchers have identified a novel drug target with the potential to overcome drug resistance and prevent tumour regrowth in cancer patients. The newly identified molecule is not currently a target for treatment, opening the potential for drug development.
Small Molecule 130
130 
Chipscreen and HISUN reach a strategic cooperation
The Pharma Data
DECEMBER 15, 2020
SH) was founded in Shenzhen on 2001, specializing in the research and development of novel small molecule drugs. HISUN PHARMACEUTICAL has developed into a “pharmaceutical industry group” composed of business including raw materials, preparations, biological drugs, innovative drugs, and commercial distribution.
Lantern Pharma Announces Scientific & Preclinical Data Indicating Blood Brain Barrier Permeability for Drug Candidate LP-184 in Glioblastoma and Potentially Other CNS Cancers
The Pharma Data
DECEMBER 14, 2020
Our mission is to transform and accelerate the cancer drug development process. If we can compress the time to clinical trials, and de-risk LP-184, we can save years of research and millions of dollars in developing treatments for GBM and potentially other CNS and brain cancers.”
DNA 52
52 
Following our pole star to a transformative collaboration
Dark Matter Blog
APRIL 8, 2020
And as we’ve launched several internal discovery programs, we are learning the rules of molecular recognition for RNA; yes, the fundamental physical constants are the same, but RNA has mixed them up in fascinating, even wacky, ways; principles that feel hard-wired for protein targets just don’t hold for RNA. We’re lucky.
RNA 52
52 
FDA Approves Klisyri (tirbanibulin) for the Treatment of Actinic Keratosis on the Face or Scalp
The Pharma Data
DECEMBER 15, 2020
Approval demonstrates our ability to execute upon the entirety of the drug development and registration process. We believe this small molecule platform has the potential beyond actinic keratosis and are leveraging the platform to develop therapies for other oncology indications.”. and in Europe.
FDA Approval 52
52 
Ovarian cancer drug enters Phase II trials
Drug Discovery World
MAY 11, 2023
The drug has already shown particular promise in ovarian cancer in a first-in-human, Phase I trial led by researchers at the ICR and The Royal Marsden NHS Foundation Trust. Algok Bio’s exclusive license agreement with BTG grants the former the rights to develop and commercialise idetrexed worldwide.
Trials 130
130 
Demystifying the ICH M10 Bioanalytical Method Validation Guidelines
Conversations in Drug Development Trends
APRIL 4, 2024
To help integrate these various regulatory standards, the International Council for Harmonization (ICH) of Technical Requirements for Pharmaceuticals for Human Use was founded in 2016. The ICH M10 guidelines aim to streamline this process, reducing redundancy in drug development and facilitating faster access to new therapies.
Novartis announces positive results from Phase II study of LNP023 in patients with paroxysmal nocturnal hemoglobinuria (PNH)
The Pharma Data
AUGUST 29, 2020
“These positive Phase II results are promising and pave the way for further evaluation of oral LNP023 as a potential monotherapy treatment and standard of care for PNH,” said John Tsai, Head Global Drug Development and Chief Medical Officer, Novartis. “We Blood 2019;134(Suppl 1):3517. 3. Schubart A, et al. 4. Merle NS, et al.
Treatment 52
52 
Gene editing in organoids: accounting for complexity in drug discovery
Drug Discovery World
JANUARY 12, 2023
Oksana Sirenko looks at the advantages and limitations of using organoids from human cell sources in drug development and drug screening. . Altering one base pair can drastically change how the gene’s protein product functions, while mutations can lead to the development of a range of genetic disorders. .
Drugs 246
246 
Understanding the Elements of a Typical IND-Enabling Package
The Premier Consulting Blog
MAY 31, 2023
As a cornerstone of the drug development process, nonclinical investigational new drug (IND)-enabling studies are essential for supporting first-in-human (FIH) dosing for novel therapeutics. Pharmacology A typical IND-enabling package includes information on the primary, secondary, and safety pharmacology of the drug.
Packaging 52
52 
Biopharma Leaders Unite To Stand With Science
The Pharma Data
SEPTEMBER 8, 2020
Its broad portfolio of oncology product candidates includes individualized and off-the-shelf mRNA-based therapies, innovative chimeric antigen receptor T cells, bi-specific checkpoint immuno-modulators, targeted cancer antibodies and small molecules.
Science 52
52 
Merck Announces Third-Quarter 2020 Financial Results
The Pharma Data
OCTOBER 26, 2020
V590 — a SARS-CoV-2 vaccine candidate in development in collaboration with the International AIDS Vaccine Initiative (IAVI) that uses a recombinant vesicular stomatitis virus (rVSV) platform, the same platform used for Merck’s approved Ebola Zaire virus vaccine, will enter Phase 1 development shortly.
Vaccine 40
40 
Biopharma Leaders Unite To Stand With Science
The Pharma Data
SEPTEMBER 8, 2020
Its broad portfolio of oncology product candidates includes individualized and off-the-shelf mRNA-based therapies, innovative chimeric antigen receptor T cells, bi-specific checkpoint immuno-modulators, targeted cancer antibodies and small molecules. the United States. the United States.
Science 52
52 
Rare autoantibody diseases: an innovative targeted pathway
Drug Target Review
JULY 7, 2023
It normally binds to and recycles internalised immunoglobin G (IgG) antibodies, which are important for fighting infections, as well as albumin, which helps move many small molecules through the blood. International Journal of Molecular Sciences. MDedge ObGyn. 2021;22(6):2922. Delaney M, Matthews DC. Hematology.
Disease 98
98 
AI-driven drug discovery: insights from Cresset
Drug Target Review
SEPTEMBER 26, 2024
Cresset delivers software solutions and contract research expertise enabling companies around the world to accelerate their small molecule discovery processes efficiently and effectively. This can result in wasted resources, time, effort and not to mention the potential for false hope in the early stages of drug development.
Drugs 64
64 
First in Human Episode #54 featuring Ahmed Hamdy
Vial
FEBRUARY 19, 2024
We can link small molecule drugs to a payload that would enter in the cell and kill it. We have the capability of different types of targets, whether small molecules or antibodies. Our antibody attaches to CD123, internalizes, then our linker cleaves only intracellularly.
Aptose Initiates Dosing of CG-806 in Patients with Acute Myeloid LeukemiaPhase 1 a/b Study of CG-806 in AML Initiates with Starting Dose of 450mg
The Pharma Data
OCTOBER 18, 2020
Aptose Biosciences is a clinical-stage biotechnology company committed to developing personalized therapies addressing unmet medical needs in oncology, with an initial focus on hematology.
Let's personalize your content